Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Study ID: 5609
NCT Number: NCT06410300
Principal Investigator: Bo Lu, MD
Department: Radiation Oncology
Eligibility: Both men and women 18 years old to 99 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
CancerClinicalTrials@health.missouri.edu